Latest Depression News

Page 2 of 14
Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.
Ada Torres
Ada Torres
8 Sept 2026
Actinogen Medical (ASX:ACW) has clarified that no undisclosed information explains recent unusual trading in its shares, pointing instead to recent underwriting of options and published updates. The biotech also reaffirmed compliance with ASX rules and provided a detailed update on its lead Alzheimer’s drug Xanamem and ongoing clinical trials.
Ada Torres
Ada Torres
4 Sept 2026
Eclipse Metals' latest testwork confirms that up to 94% of neodymium and praseodymium are locked in identifiable REE minerals at Grønnedal, underpinning a promising beneficiation strategy ahead of flotation trials.
Maxwell Dee
Maxwell Dee
3 Sept 2026
Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.
Ada Torres
Ada Torres
1 Sept 2026
Actinogen Medical has locked in full underwriting for nearly 127 million unlisted options, guaranteeing $4.77 million in fresh funding as it approaches pivotal Alzheimer’s trial results due in November.
Ada Torres
Ada Torres
1 Sept 2026
BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.
Victor Sage
Victor Sage
31 Aug 2026
Entropy Neurodynamics (ASX:ENP) reported a 30% rise in income and a narrower loss for FY26, driven by clinical progress in its IV-infused psilocin therapy TRP-8803, including promising Phase 2 results in Binge Eating Disorder and a new multi-indication basket study.
Ada Torres
Ada Torres
28 Aug 2026
Mach7 Technologies reported a 17.4% revenue drop to $27.9 million and a 44% increase in net loss to $8.9 million for FY26, driven by a strategic transition to a subscription model and cost base restructuring.
Victor Sage
Victor Sage
28 Aug 2026
Actinogen Medical reported a $15.38 million loss for FY2026 while progressing its lead Alzheimer's drug Xanamem toward pivotal trial results expected this November. The company secured regulatory alignment and strengthened its cash position to fund operations through mid-2027.
Ada Torres
Ada Torres
27 Aug 2026
Rubicon Water's FY26 results reveal an 11.6% revenue drop to $61.1 million and a net loss widening to $15.7 million, impacted by US federal funding delays and currency headwinds. Despite this, the company secured $28.4 million in second-half contracts and holds a $47 million major project pipeline, underpinning confidence for FY27 growth.
Maxwell Dee
Maxwell Dee
24 Aug 2026
Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.
Ada Torres
Ada Torres
30 July 2026
Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.
Ada Torres
Ada Torres
29 July 2026

Browse the archive

Full archive